Product information and disease descriptionProduct descriptionProduct information
Product comparison
20 evidence topics · 16 sources
Manufacturer statement of competitive factors and comparator classes
Dosage forms, dosing frequency, and administration: deucravacitinib, apremilast, and icotrokinra labels
| Feature | Deucravacitinib label text |
|---|---|
| Dosage form and strength | “SOTYKTU (deucravacitinib) tablets are supplied in 6 mg strength for oral administration.” |
| Accumulation with once-daily dosing | “The accumulation of deucravacitinib was <1.4-fold following once daily dosing in healthy subjects.” |
| Tablet handling | “Do not crush, cut, or chew the tablets.” |
| Food | “No clinically significant differences in the pharmacokinetics of deucravacitinib were observed following administration of a high-fat, high-calorie meal” |
| Feature | Apremilast label text |
|---|---|
| Dosage forms and strengths, immediate release | “OTEZLA (apremilast) tablets are supplied in 10 mg, 20 mg, and 30 mg strengths for oral administration.” |
| Dosage form and strength, extended release | “OTEZLA XR (apremilast) extended-release tablets are supplied in a 75 mg strength for oral administration.” |
| Switching between twice-daily and once-daily formulations | “Patients treated with OTEZLA 30 mg twice daily may be switched to OTEZLA XR 75 mg once daily the day following the last dose of OTEZLA 30 mg.” |
| Food | “Administer OTEZLA/OTEZLA XR with or without food.” |
| Tablet handling | “Swallow tablets whole. Do not crush, split, or chew.” |
Elimination half-life, steady state, and metabolism: deucravacitinib, apremilast, and icotrokinra labels
| Parameter | Deucravacitinib label text |
|---|---|
| Half-life | “The terminal half-life of deucravacitinib was 10 hours.” |
| Active metabolite | “The active deucravacitinib metabolite, BMT-153261, has comparable potency to the parent drug” |
| Metabolic pathways | “Deucravacitinib is also metabolized by CYP2B6, CYP2D6, carboxylesterase (CES) 2, and uridine glucuronyl transferase (UGT) 1A9.” |
Contraindications and hypersensitivity: deucravacitinib, apremilast, and icotrokinra labels
| Feature | Deucravacitinib label text |
|---|---|
| Contraindication | “SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU” |
| Hypersensitivity | “Hypersensitivity reactions, such as angioedema, have been reported in subjects receiving SOTYKTU.” |
| Feature | Icotrokinra label text |
|---|---|
| Contraindications | “None.” |
Infection, hepatitis, and immunization requirements: deucravacitinib and icotrokinra labels
| Requirement | Icotrokinra label text |
|---|---|
| Infection risk | “Medicines that interact with the immune system may increase the risk of infection.” |
| Active infection | “Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated.” |
| Tuberculosis monitoring | “Monitor patients for signs and symptoms of active TB during and after ICOTYDE treatment.” |
| Active tuberculosis | “Avoid administering ICOTYDE to patients with active TB.” |
| Immunizations before treatment | “Prior to initiating therapy with ICOTYDE, complete immunizations according to current immunization guidelines.” |
| Vaccine response | “No data are available on the response to live or inactive vaccines.” |
Pretreatment screening requirements of deucravacitinib and apremilast
“Before initiating treatment, patients should be screened for tuberculosis (TB) and viral hepatitis, which is not required, for example, before starting apremilast” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory and clinical monitoring: deucravacitinib, apremilast, and icotrokinra labels
| Monitoring item | Icotrokinra label text |
|---|---|
| Reduced renal function | “Monitor for potential adverse reactions when ICOTYDE is used in patients with an estimated glomerular filtration rate (eGFR) <60 mL/min” |
| Anti-drug antibodies | “In four Phase 3 clinical studies through Week 52, 9.6% (199/2083) of subjects treated with ICOTYDE developed anti-drug antibodies.” |
| Neutralizing antibodies | “No neutralizing antibodies were detected.” |
Drug interactions: deucravacitinib, apremilast, and icotrokinra labels
| Interaction | Apremilast label text |
|---|---|
| Strong CYP450 inducers | “Co-administration with strong CYP450 inducers (such as rifampin) decreases apremilast exposure and may result in loss of efficacy of OTEZLA/OTEZLA XR” |
| Interaction | Icotrokinra label text |
|---|---|
| Clinical interaction studies | “No formal drug-drug interaction studies have been conducted with icotrokinra. No clinically significant drug interactions have been identified.” |
| Cytochrome P450 enzymes | “Icotrokinra does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.” |
Pregnancy, lactation, pediatric use, and geriatric use: deucravacitinib, apremilast, and icotrokinra labels
Renal and hepatic impairment: deucravacitinib, apremilast, and icotrokinra labels
| Impairment | Apremilast label text |
|---|---|
| Severe renal, immediate release | “In adult patients with severe renal impairment, reduce the maintenance dosage to OTEZLA 30 mg once daily.” |
| Severe renal, extended release | “OTEZLA XR is not recommended for adult patients with severe renal impairment; the appropriate dosage for these patients has not been determined” |
| Hepatic, population studied | “Apremilast pharmacokinetics were characterized in subjects with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment.” |
| Hepatic, dosage | “No dosage adjustment is necessary in these patients.” |
Selectivity for TYK2 over JAK1, JAK2, and JAK3 across allosteric TYK2 inhibitors
“Orthosteric inhibitors with activity against TYK2 (e.g., brepocitinib and ropsacitinib) bind the JAK homology 1 (JH1) domain and compete with the natural substrate, ATP, to occupy the active site” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zasocitinib bound the TYK2 Janus homology 2 domain with an inhibitory constant of 0.0087 nM, demonstrating more than 1 millionfold selectivity over Jak1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, deucravacitinib has an 87-fold greater biochemical selectivity for the TYK2/JH2 domain compared to the JAK1/JH2 domain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In fact, there is no measurable inhibition of JAK1, JAK2, or JAK3 by envudeucitinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Envudeucitinib has a molecular structure that separates it from other TYK2 inhibitors, with a modified arrangement and strategic deuteration sites that contribute to its metabolic stability and pharmacodynamic properties.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zasocitinib is an allosteric TYK2 inhibitor with a mechanism of action analogous to that of deucravacitinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It has been bioengineered to demonstrate enhanced selectivity for the TYK2 JH2 domain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of TYK2 inhibition across the dosing interval and dosing frequency of TYK2 inhibitors
“In preclinical and phase 1 studies, oral administration of envudeucitinib twice daily achieved maximal (90% inhibitory concentration [IC90]) TYK2 inhibition over 24 h, highlighting a level of sustained target engagement that distinguishes envudeucitinib from other oral immunomodulators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It also exhibits >24 hours of steady state time above IC50 and IC90, indicating prolonged and consistent TYK2 targeting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Simulated clinical concentrations of 30 mg zasocitinib once daily exceeded the TYK2 half-maximal inhibitory concentration for 24 hours, maintaining >90% daily inhibition, with no Jak1/2/3 inhibition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy and tolerability of deucravacitinib relative to apremilast and injectable biologics in narrative reviews
“When compared with apremilast, deucravacitinib exhibits improved tolerability, with fewer discontinuations due to adverse events, as well as greater efficacy, with ≥ 75% improvement from baseline in Psoriasis Area and Severity Index score (PASI 75) response rates of approximately 55% vs. 37% at week 16” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While the efficacy of deucravacitinib is lower than that of most injectable IL-23 or IL-17 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given its mechanism of action, deucravacitinib causes less modification of cytokine signaling vs other JAK inhibitors, resulting in a narrower adverse effect (AE) profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is the only JAK or TYK2 inhibitor indicated for psoriasis that does not have a boxed warning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zasocitinib versus apremilast at week 24 as summarized in a review
Head-to-head trial: risankizumab versus deucravacitinib in biologic-naive moderate psoriasis, week 16
“IMMpactful is a phase 4 multicenter, randomized, open-label, efficacy assessor-blinded, active comparator study examining the safety and efficacy of RZB compared with DEU in patients with moderate psoriasis who are candidates for systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In period A, patients either received a single subcutaneous injection of RZB 150 mg on day 1 and week 4 or oral DEU 6 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 393 patients enrolled in IMMpactful, 131 were randomized to RZB and 262 to DEU (1 patient did not receive study drug) in period A (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A significantly higher proportion of patients treated with RZB achieved PASI 90 (57.3% versus 22.9%), sPGA 0/1 (80.2% versus 39.7%), PASI 100 (27.5% versus 6.5%), and sPGA 0 (27.5% versus 6.9%) compared with patients treated with DEU at week 16 (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A greater proportion of patients treated with RZB (64.1% [95% CI 55.9%, 72.3%]) achieved DLQI 0/1 compared with patients treated with DEU (30.5% [95% CI 25.0%, 36.1%]) (Fig. 5A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In period A, TEAEs were reported in 33.6% of patients treated with RZB compared with 42.9% of patients treated with DEU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One potential limitation is that this study employs an open-label design rather than a double-blinded design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AbbVie funded this study (NCT06333860) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Matching-adjusted indirect comparison: deucravacitinib versus adalimumab through week 112
“Before reweighting, on average, patients in the POETYK PSO-LTE (N = 329) versus the REVEAL (N = 345) extension were older, had a lower body weight, received more prior systemic treatments, and had higher baseline PASI scores and week 16 placebo PASI 75 and PASI 90 response rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following reweighting, adjusted week 112 PASI 75 response rates were significantly higher for deucravacitinib versus adalimumab (67.2% vs. 54.0%; mean difference [95% CI], 13.2 [4.0–22.5] percentage points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib had a numerically higher adjusted week 112 PASI 90 response rate (41.3% vs. 34.0%; mean difference [95% CI], 7.3 [−2.0 to 16.7] percentage points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatments had similar week 52 adjusted PASI 75 and PASI 90 response rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was sponsored by Bristol Myers Squibb.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analyses of TYK2 inhibitors and other oral agents
“In total, 13 RCTs (five for TYK2 inhibitors and eight for PDE4 inhibitors) involving 5274 patients were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, deucravacitinib (3 mg BID, 6 mg QD, 6 mg BID, and 12 mg QD), and ropsacitinib (400 mg QD) showed superior efficacy than apremilast (30 mg BID).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of safety, deucravacitinib or ropsacitinib at any dose did not lead to a higher incidence of AEs than apremilast (30 mg BID).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12- 16 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tofacitinib (10 mg BID) was considered the most unsafe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study included 66 trials of 27,074 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib has demonstrated moderate efficacy and tolerability; however, additional head-to-head comparative trials are warranted to substantiate its effects due to the paucity of existing studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer cross-trial comparison: PASI 100 with envudeucitinib, icotrokinra, and zasocitinib
Manufacturer cross-trial comparison: itch improvement of at least 4 points on the PSSD at weeks 2, 4, and 16
Absence of head-to-head trials and formal indirect comparisons that include envudeucitinib
“Additionally, direct (e.g., head-to-head) and formal indirect (e.g., meta-analyses) comparisons of oral agents for the treatment of psoriasis are not presently available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By achieving full target engagement without compromising safety, envudeucitinib may offer efficacy comparable to biologics (e.g., IL-23 and IL-17 inhibitors) in an oral formulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medical writing assistance was funded by Alumis Inc. The journal’s Rapid Service Fee was funded by Alumis Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, comparisons between studies are limited as varying methodologies were used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As more TYK2 inhibitors, such as zasocitinib and envudeucitinib, emerge, additional studies will be essential to delineate differences in efficacy, safety, and long-term outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote